Joint national committee VI: Individualized versus indiscriminate therapy for hypertension
The treatment of hypertension has progressed from a few nontoxic choices to the close to 60 individual drugs listed in the recommendations of the Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Many combination drugs are also listed for use. The JNC documents have suggested initial therapy with diuretic or b-blocker since 1993. Practioners have followed these suggestions or not followed them on the basis of their personal bias. Since the 1997 JNC VI report, several studies that seem to support an individualistic approach to treatment have been reported. This is an exciting time in hypertension research. Clinicians who treat this common disorder will continue to line up as indiscriminate or individualistic prescribers, depending on their interpretation of the available data. We expect the hypertensive patient to be the winner of this increased attention.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 3.Berlowitz DR, Ash AS, Hickey EC, et al.: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339:1957–1963. Provider noncompliance is more complex than avoidance of dose titration. This study in a Veterans Affairs population points out the need for continued reassessment of our management of each hypertensive patient.PubMedCrossRefGoogle Scholar
- 5.Curb JD, Pressel SL, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886–92. This article has helped dispel the belief that diuretics are dangerous for diabetic patients.PubMedCrossRefGoogle Scholar
- 10.Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611–616. This study is the first to compare b-blocker and ACE inhibitor. It suggests that both are appropriate for cardiac protection in hypertensive patients. This finding is supported by the UK Prospective Diabetes Study Group’s similar finding .PubMedCrossRefGoogle Scholar
- 12.UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ 1998, 317:713–720.Google Scholar
- 13.UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998, 317:703–713.Google Scholar
- 14.Wang JG, Staessen JA, Gong L, et al.:Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000, 160:211–220. Another study suggesting that initial therapy with dihydropyridine may not be as risky as previously thought.PubMedCrossRefGoogle Scholar
- 17.Hansson L, Zachetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755–1762. Reversed stepped-care works, is tolerated, and is not associated with increased risk as blood pressure is lowered to less than 80 mm Hg diastolic.PubMedCrossRefGoogle Scholar
- 18.Dahlof B, Hansson L, Lindholm L, et al.: STOP-Hypertension-2: A prospective intervention trial of ‘newer’ versus ‘older’ treatment alternatives in old patients with hypertension. Blood Pres 1993, 2:136–141.Google Scholar
- 19.The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000, 342:145–153. The use of ramipril was beneficial, even in normotensive patients. Is this drug class or this medication special?CrossRefGoogle Scholar
- 21.Burnett JC: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17(suppl 1):S37-S43.Google Scholar
- 22.Materson BJ, Reda DJ, Cushman WC, et al.: Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. Veterans Affairs Cooperative Study Group on Antihypertensive Agents [Corrected in Am J Hypertens. 1995, 8:189-192]. N Engl J Med 1993, 328:914–921.PubMedCrossRefGoogle Scholar